Vanda Pharmaceuticals
VNDA
125 hedge funds and large institutions have $621M invested in Vanda Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 49 increasing their positions, 42 reducing their positions, and 25 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 42
2.42% more ownership
Funds ownership: 88.55% → 90.97% (+2.4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less funds holding
Funds holding: 137 → 125 (-12)
13% less capital invested
Capital invested by funds: $711M → $621M (-$89.8M)
48% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 25
92% less call options, than puts
Call options by funds: $768K | Put options by funds: $9.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$17M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$8.68M |
| 3 |
State Street
Boston,
Massachusetts
|
+$7.22M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$6.24M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$5.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$9.78M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$7.34M |
| 3 |
Millennium Management
New York
|
-$4.65M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$4.37M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
-$3.83M |
VNDA Hedge Fund Activity: Q4 2017 in Review
125 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2017, worth a combined $621M — down 13% from $711M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of VNDA and 13 opened new positions — a net loss of 12 holders — while 42 trimmed existing stakes and 49 added.
The largest buyer was Armistice Capital, adding an estimated $17M. The largest seller was Citadel Advisors, cutting an estimated $9.78M.
- 125 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2017, down from 137 in Q3 2017.
- Funds reported $621M of Vanda Pharmaceuticals stock for Q4 2017, down 13% quarter-over-quarter.
- 13 funds opened new Vanda Pharmaceuticals positions in Q4 2017 and 25 closed out, a net change of -12 holders.
- The largest Vanda Pharmaceuticals buyer in Q4 2017 was Armistice Capital, an estimated $17M added.
- The largest Vanda Pharmaceuticals seller in Q4 2017 was Citadel Advisors, an estimated $9.78M sold.
Based on aggregated 13F filings for Q4 2017.